Why this startup is taking its AI to predict breast-cancer risk directly to patients
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
Pharmalittle: GLP-1s seen as lifestyle drugs; Merck, Daiichi setback
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating.…
Gifts from pharma companies keep on giving, a new study finds
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Enveda weight loss maintenance pill mimics exercise in early tests
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
Pharmalittle: Sanofi experiencing drug shortages, Jazz buying Actio
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Pharmalittle: Novo discloses setback, Replimune drug endorsed
And so, another working week will soon come to a close. Not a moment too soon, yes? This…
Pharmalittle: FDA panel nixed Duchenne drug, Hims & Hers sued| STAT
Top of the morning to you, and a fine one it is. Skies are gray but rain is…
Pharmalittle: FDA panel backs pharmacies to make peptides
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
FDA is urged by advocacy group to ban DTC prescription drug ads
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Barriers may keep Merck’s new cholesterol drug from success
A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name…